Abstract

Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet

Author(s): Hazdi Siti Nursaqifah, Phang Hiu Ching, Ng Zhi Qi, Chew Yik Ling, Uddin ABM Helal, Sarker Zaidul Islam, Lee Siew-Keah, Liew Kai Bin

Issue: Nov/Dec 2023 - Volume 27, Number 6

Page(s): 522-527

Download in electronic PDF format for $75
  • Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet Page 1
  • Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet Page 2
  • Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet Page 3
  • Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet Page 4
  • Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet Page 5
  • Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet Page 6

Abstract

Orally disintegrating tablets, which were originally developed in the pharmaceutical field to improve the compliance of patients who had difficulty swallowing tablets, have become a preferable choice in solid dosage forms since it brings advantages to the patients and consumers in the healthcare system. Among the advantages of this novel dosage form are a faster onset of action, improved bioavailability, and the ease of administration as it can be taken without water. However, there are still some limitations of orally disintegrating tablets that need to be overcome, including a lack of mechanical strength, an unpleasant taste of the drug in the mouth, and a stability issue due to its hygroscopicity nature. This objective of this study was to identify the composition of co-processed excipients comprising of mannitol, microcrystalline cellulose, xylitol, and crospovidone or croscarmellose sodium in order to formulate orally disintegrating tablets containing memantine hydrochloride. This study was carried out in two stages. Firstly, orally disintegrating tablets containing memantine hydrochloride with 6 different formulations, which differed in the percentage of crospovidone or croscarmellose sodium, were formulated and manufactured. Secondly, the orally disintegrating tablets obtained were evaluated through pre- and post-compression tests based on the standard for orally disintegrating tablets. Formulation 3, which consisted of 10% xylitol, 10% mannitol, 72% microcrystalline cellulose, and 8% crospovidone, was chosen as the optimum formulation for the co-processed excipient since it was the fastest disintegration process among all the formulations in the study. In addition, Formulation 3 also showed the acceptable and satisfying results in other evaluation tests such as – weight variation test, hardness test, and friability test. The co-processed excipient comprising of 10% xylitol, 10% mannitol, 72% microcrystalline cellulose, and 8% crospovidone, which is characterized by improved functionalities such as a fast disintegration process, plays a crucial role in the application of orally disintegrating tablets.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2023
Pg. 522-527
May/Jun 2022
Pg. 255-263
Sep/Oct 2022
Pg. 370-377
Author(s): Ejeta Fikadu
Nov/Dec 2023
Pg. 512-521
Jan/Feb 2022
Pg. 80-87
Sep/Oct 2024
Pg. 423-431
Sep/Oct 2024
Pg. 402-407
Nov/Dec 2020
Pg. 509-514
Sep/Oct 2001
Pg. 389-390
Author(s): Allen Loyd V Jr
Nov/Dec 2024
Pg. 502-508
Mar/Apr 2022
Pg. 155-162
Nov/Dec 2015
Pg. 511
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 233-239
Mar/Apr 2020
Pg. 148-155
May/Jun 2023
Pg. 240-249
Mar/Apr 2022
Pg. 163-174
Nov/Dec 2018
Pg. 516-526
Jul/Aug 2006
Pg. 316-317
May/Jun 2004
Pg. 181-185
Jul/Aug 2000
Pg. 306-310
Author(s): Allen Loyd V Jr